Month: June 2020

Press ReleaseParis La Défense, 15 June 2020Albioma enters the SBF 120 indexFollowing the quarterly review of the Euronext Paris indices, the Scientific Advisory Board of the Indices decided to include Albioma in the SBF 120 and CAC Mid 60 indices. This decision will take effect as of 19 June 2020, after market close.Inclusion in this benchmark index, which covers the 120 largest stocks on the Paris stock exchange in terms of market capitalisation and liquidity, represents a new milestone for Albioma, which will be able to benefit from the positive effects of increased visibility amongst the financial community.Frédéric Moyne, Chairman and Chief Executive Officer of Albioma, declared: “We are very pleased to learn that we have been included in the SBF 120 benchmark index, which reflects investor interest in the energy transition...

Communiqué de presseParis La Défense, le 15 juin 2020Albioma entre dans l’indice SBF 120À la suite de la révision trimestrielle des indices d’Euronext Paris, le conseil scientifique des Indices a pris la décision d’inclure Albioma dans les indices SBF 120 et CAC Mid 60. Cette décision prendra effet à compter du 19 juin 2020, après clôture du marché.L’entrée dans cet indice de référence, qui regroupe les 120 premières valeurs de la place de Paris en termes de capitalisation boursière et de liquidité, représente une nouvelle étape importante pour Albioma qui pourra bénéficier des effets positifs liés à une visibilité accrue auprès de la communauté financière.Frédéric Moyne, Président-Directeur Général d’Albioma, déclare : « Nous avons le grand plaisir d’apprendre notre entrée dans l’indice de référence SBF 120, qui témoigne...

Innofactor Oyj:n sisäpiiritieto 15.6.2020 klo 8.40Ruotsalainen ammattiliitto on päättänyt jatkaa yhteistyötä Innofactorin kanssa liideihin, tiketöntiin ja kurssinhallintaan keskittyvän jäsenhallintajärjestelmänsä jatkokehittämiseksi. Järjestelmä pohjautuu Microsoft Dynamics 365 -ohjelmistoon sekä Innofactorin Membership Management System (MMS) -jäsenhallintaratkaisuun. Projektin toimituksen on suunniteltu alkavan heinäkuussa 2020 ja päättyvän kesäkuussa 2021. Hankkeen arvonlisäveroton hinta on noin 1 000 000 euroa.Espoossa 15.6.2020INNOFACTOR OYJSami Ensio, toimitusjohtajaLisätietoja:Sami Ensio, toimitusjohtajaInnofactor OyjPuh. 050 584 2029sami.ensio@innofactor.comJakelu:NASDAQ HelsinkiKeskeiset mediatwww.innofactor.fiInnofactorInnofactor on johtava yritysten, julkishallinnon ja kolmannen sektorin modernin digitaalisen organisaation...

Innofactor Plc Inside Information, on June 15, 2020, at 8:40 Finnish timeA Swedish Trade Union has decided to continue the collaboration with Innofactor as the provider for further development of the membership management solution focusing on leads, ticket management and course solution with Microsoft Dynamics 365 and Innofactor’s Membership Management System MMS as the foundation. The project is planned to be delivered from July 2020 to June 2021. The price (excluding VAT) for the project is approximately EUR 1,000,000.Espoo, June 15, 2020INNOFACTOR PLCSami Ensio, CEOAdditional information:Sami Ensio, CEOInnofactor PlcTel. +358 50 584 2029sami.ensio@innofactor.comDistribution:NASDAQ HelsinkiMain mediawww.innofactor.comInnofactorInnofactor is the leading driver of the modern digital organization in the Nordic Countries for its over 1,500...

SHANGHAI, China, June 15, 2020 (GLOBE NEWSWIRE) — Hua Medicine (the “Company”, Stock Code: 2552. HK), a leading innovative drug development company focused on developing novel therapies for the treatment of diabetes, announced post-analysis results from dorzagliatin’s 24-week monotherapy trial SEED, (also known as HMM0301).The following findings from the SEED study were presented in oral and symposium presentations at the American Diabetes Association’s 80th Scientific Session digitally:Fast on-set of action (effective HbA1c reduction in 4 weeks)Significant improvement of β-cell function in treatment group as compared to the placebo groupSignificant reduction of 2-hour post-prandial glucose reduction was observed in treatment group as compared to the placebo groupGood safety profile and tolerance of dorzagliatin with limited hypoglycemia...

中國上海, June 15, 2020 (GLOBE NEWSWIRE) — 華領醫藥（「公司」，香港聯交所股份代號：2552.HK），一家針對全球糖尿病患者尚未滿足的臨床需求研發全球原創新藥的生物技術公司，今天公佈了dorzagliatin單藥治療臨床試驗SEED（也稱為HMM0301）的24周事後分析資料結果。在美國糖尿病協會（ADA）第80屆科學年會線上會議上，華領醫藥通過口頭報告和專題討論會對SEED研究進行了報告：快速起效，糖化血糖蛋白（HbA1c）在用藥4周後有效下降相比安慰劑對照組，治療組β細胞功能明顯改善相比安慰劑對照組，治療組的餐後2小時血糖值顯著下降安全性和耐受性好，低血糖發生率低，治療組和安慰劑組的不良事件發生率相似24周持續有效良好的應答率“Dorzagliatin的事後分析資料建立在此前24周頂線資料的積極結果基礎上，”華領醫藥首席執行官兼首席科學官陳力博士說，“結果證明了dorzagliatin具有修復2型糖尿病患者血糖穩態的潛力，進一步支持了我們探索2型糖尿病基石治療的努力。”通過標記物測量，dorzagliatin顯示出了對β細胞功能的明顯改善資料表明，與安慰劑對照組相比，dorzagliatin治療組的β細胞功能顯著改善（通過HOMA2-β1指數測量），治療組增加2.56％，安慰劑組減少0.72％。在試驗中，Dorzagliatin在血糖控制方面展現出積極成效，並具有良好的安全性對dorzagliatin單藥治療III期臨床試驗的事後分析表明，dorzagliatin在治療2型糖尿病方面顯示出了以下積極前景：Dorzagliatin治療組的糖化血紅蛋白（HbA1c）相對基線降低了1.07%，組間差異具有顯著的統計學意義餐後2小時血糖顯著降低（治療組下降2.83mmol/L，安慰劑組上升0.50mmol/L，p

中国上海, June 15, 2020 (GLOBE NEWSWIRE) — 华领医药（「公司」，香港联交所股份代号：2552.HK），一家针对全球糖尿病患者尚未满足的临床需求研发全球原创新药的生物技术公司，今天公布了dorzagliatin单药治疗临床试验SEED（也称为HMM0301）的24周事后分析数据结果。在美国糖尿病协会（ADA）第80届科学年会线上会议上，华领医药通过口头报告和专题讨论会对SEED研究进行了报告：快速起效，糖化血糖蛋白（HbA1c）在用药4周后有效下降相比安慰剂对照组，治疗组β细胞功能明显改善相比安慰剂对照组，治疗组的餐后2小时血糖值显著下降安全性和耐受性好，低血糖发生率低，治疗组和安慰剂组的不良事件发生率相似24周持续有效良好的应答率“Dorzagliatin的事后分析数据建立在此前24周顶线数据的积极结果基础上，”华领医药首席执行官兼首席科学官陈力博士说，“结果证明了dorzagliatin具有修复2型糖尿病患者血糖稳态的潜力，进一步支持了我们探索2型糖尿病基石治疗的努力。”通过标记物测量，dorzagliatin显示出了对β细胞功能的明显改善数据表明，与安慰剂对照组相比，dorzagliatin治疗组的β细胞功能显著改善（通过HOMA2-β1指数测量），治疗组增加2.56％，安慰剂组减少0.72％。在试验中，Dorzagliatin在血糖控制方面展现出积极成效，并具有良好的安全性对dorzagliatin单药治疗III期临床试验的事后分析表明，dorzagliatin在治疗2型糖尿病方面显示出了以下积极前景：Dorzagliatin治疗组的糖化血红蛋白（HbA1c）相对基线降低了1.07%，组间差异具有显著的统计学意义餐后2小时血糖显著降低（治疗组下降2.83mmol/L，安慰剂组上升0.50mmol/L，p

Danny Callow appointed as President and Chief Executive Officer;Scott Eldridge appointed as Non-Executive Chairman of the Board;Jan-Erik Back appointed as Vice-Chairman, Strategy of the Board;John Begeman appointed as Lead Independent Director of the Board; andProposed change of name to “Avion2 Gold Inc.”TORONTO, June 15, 2020 (GLOBE NEWSWIRE) — African Gold Group, Inc. (TSX-V: AGG) (“AGG” or the “Company”) is pleased to announce the following structural changes to the board of directors (the “Board”) and management of the Company as it moves towards construction and first gold at its flagship Kobada Gold Project in southern Mali.Highlights include the appointment of Danny Callow appointed as President and Chief Executive Officer, Scott Eldridge as Non-Executive Chairman of the Board, Jan-Erik Back as Vice-Chairman, Strategy of...